Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN

NCCN has been awarded a $1M research grant from Merck &Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Goret CC, Goret NE, Ozkan OF, Karaayvaz M Abstract Foreign body reactions may develop against exogenous or certain endogenous materials. Cases of suture granuloma that develop against nonabsorbable suture material are rare complications of thyroid surgery. Because of these postoperative complications, a history of cancer prior to the operation suggests recurrence of cancer. Appropriate clinical, radiological, and pathological evaluation is highly important in such cases. Postoperative foreign bodies may remain undetected for years, but they sometimes cause lethal complications. KEY WORDS: Cancer mimick...
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M Abstract BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-sma...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
When a patient has an inherited cancer-associated gene, it is desirable, but not easy, to have other family members tested. Using a commercial lab to circumvent nettlesome privacy regulations may help.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
PANCREATIC cancer doesn ’t have any specific causes, but there are various risk factors which could increase the chance of developing the disease. Having diabetes is one of them.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
THE first UK patient has received radiotherapy using a machine which could one day cure some cancers in a single treatment.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Barry Dolling, 65, from Selsdon in Surrey, has become the first person in the UK to receive radiotherapy treatment from the MR Linac machine at the Royal Marsden in London.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
PMID: 30243508 [PubMed - in process]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Annual detection of prostate cancer in men 70 and older costs Medicare an estimated $1.2 billion every three years, and most costs are treatment-related, according to new findings.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Effective first-line chemotherapy and targeted therapy in patients with metastatic breast cancer may offer the possibility of cure.Chinese Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Authors: Shen D, Yu X, Wu Y, Chen Y, Li G, Cheng F, Xia L Abstract INTRODUCTION: Retinoic acid X receptors play key roles in tumor cell proliferation, differentiation, apoptosis and angiogenesis via transcriptional regulation. Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL). Its cancer prevention and treatment potentials in various tumors have been under investigation over the past decade. Areas covered: This review summarizes the efficacy and underlying mechanisms of bexarotene for the treatment of multiple cancers based on...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Cutaneous T cell lymphoma | Grants | Lung Cancer | Lymphoma | Merck | Non-Small Cell Lung Cancer | Radiation Therapy | Study | T-cell Lymphoma